99 related articles for article (PubMed ID: 2538224)
1. Interaction of several nucleoside triphosphate analogues and 10-hydroxycamptothecin with human DNA topoisomerases.
Liu SY; Hwang BD; Liu ZC; Cheng YC
Cancer Res; 1989 Mar; 49(6):1366-70. PubMed ID: 2538224
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of topoisomerase II by 8-chloro-adenosine triphosphate induces DNA double-stranded breaks in 8-chloro-adenosine-exposed human myelocytic leukemia K562 cells.
Yang SY; Jia XZ; Feng LY; Li SY; An GS; Ni JH; Jia HT
Biochem Pharmacol; 2009 Feb; 77(3):433-43. PubMed ID: 19014910
[TBL] [Abstract][Full Text] [Related]
3. Nucleoside triphosphates inhibit ADP, collagen, and epinephrine-induced platelet aggregation: role of P2Y₁ and P2Y₁₂ receptors.
Aslam M; Sedding D; Koshty A; Santoso S; Schulz R; Hamm C; Gündüz D
Thromb Res; 2013 Nov; 132(5):548-57. PubMed ID: 24071464
[TBL] [Abstract][Full Text] [Related]
4. Effects of ATP and inhibitory factors on the activity of vaccinia virus type I topoisomerase.
Foglesong PD; Bauer WR
J Virol; 1984 Jan; 49(1):1-8. PubMed ID: 6317884
[TBL] [Abstract][Full Text] [Related]
5. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
6. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate.
Parker WB; Shaddix SC; Chang CH; White EL; Rose LM; Brockman RW; Shortnacy AT; Montgomery JA; Secrist JA; Bennett LL
Cancer Res; 1991 May; 51(9):2386-94. PubMed ID: 1707752
[TBL] [Abstract][Full Text] [Related]
7. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Kaufmann SH
Cancer Res; 1991 Feb; 51(4):1129-36. PubMed ID: 1705167
[TBL] [Abstract][Full Text] [Related]
8. Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors.
Peleg R; Romzova M; Kogan-Zviagin I; Apte RN; Priel E
BMC Cancer; 2014 Dec; 14():910. PubMed ID: 25472619
[TBL] [Abstract][Full Text] [Related]
9. Hypersensitivity of NIH3T3 cells transformed by H-ras gene to DNA-topoisomerase-I inhibitors.
Ohira T; Nishio K; Kanzawa F; Ishida T; Ohe Y; Arioka H; Funayama Y; Ogasawara H; Kato H; Saijo N
Int J Cancer; 1996 Sep; 67(5):702-8. PubMed ID: 8782662
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of nucleoside triphosphates on nucleolar RNA synthesis.
Nagamine Y; Mizuno D; Natori S
J Biochem; 1979 Mar; 85(3):839-45. PubMed ID: 34601
[TBL] [Abstract][Full Text] [Related]
11. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.
Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC
Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247
[TBL] [Abstract][Full Text] [Related]
12. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells.
Minderman H; Wrzosek C; Cao S; Utsugi T; Kobunai T; Yamada Y; Rustum YM
Cancer Chemother Pharmacol; 2000; 45(1):78-84. PubMed ID: 10647506
[TBL] [Abstract][Full Text] [Related]
14. Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II.
Li Y; Luan Y; Qi X; Li M; Gong L; Xue X; Wu X; Wu Y; Chen M; Xing G; Yao J; Ren J
Toxicol Sci; 2010 Dec; 118(2):435-43. PubMed ID: 20855424
[TBL] [Abstract][Full Text] [Related]
15. The importance of nucleoside triphosphate inhibition of liver glycogen synthase phosphatase activity.
Gilboe DP; Nuttall FQ
Biochim Biophys Acta; 1989 May; 991(2):340-6. PubMed ID: 2541795
[TBL] [Abstract][Full Text] [Related]
16. DNA topoisomerases I and II in human mature sperm cells: characterization and unique properties.
Har-Vardi I; Mali R; Breietman M; Sonin Y; Albotiano S; Levitas E; Potashnik G; Priel E
Hum Reprod; 2007 Aug; 22(8):2183-9. PubMed ID: 17656417
[TBL] [Abstract][Full Text] [Related]
17. [Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11].
Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
Noshuyo Byori; 1994; 11(1):59-64. PubMed ID: 8162152
[TBL] [Abstract][Full Text] [Related]
18. Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates.
Liou JY; Dutschman GE; Lam W; Jiang Z; Cheng YC
Cancer Res; 2002 Mar; 62(6):1624-31. PubMed ID: 11912132
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
[TBL] [Abstract][Full Text] [Related]
20. Structural requirements for the activation of Escherichia coli CTP synthase by the allosteric effector GTP are stringent, but requirements for inhibition are lax.
Lunn FA; MacDonnell JE; Bearne SL
J Biol Chem; 2008 Jan; 283(4):2010-20. PubMed ID: 18003612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
